Zai Lab Prices $250M PIPE at $22.04 per ADS to Fund Zoci Development
ZLAB sits 43% above its 52-week low of $15.96.
Summary
Zai Lab sold 11.34 million ADSs at $22.04 each in a $250 million private placement led by TCGX, with proceeds earmarked mainly for global development of its DLL3 ADC zoci. The raise is dilutive but priced near the current market and backed by a deep roster of specialist healthcare funds.
Key Events · Financing and Capital Events · ZLAB
-
Zai Lab Prices $250M Private Placement
A securities purchase agreement signed October 22, 2026 covers 11,340,000 ADSs (each representing 10 ordinary shares) at $22.04 per ADS, for gross proceeds of approximately $250 million before placement agent fees and expenses.
-
Proceeds Earmarked for Zoci Pipeline
Net proceeds will primarily fund continued global development of zocilurtatug pelitecan (zoci), the DLL3-targeting ADC, plus working capital and general corporate purposes.
-
Blue-Chip Investor Roster Led by TCGX
TCGX led the financing, with participation from abrdn World Healthcare Fund, ADAR1 Capital Management, Balyasny Asset Management, Cormorant Asset Management, Frazier Life Sciences, RA Capital Management, RTW Investments, Sirenia Capital Management, Wellington Management and Woodline Partners.
-
Closing Expected October 27, 2026
The PIPE closing is expected on or about October 27, 2026, subject to customary closing conditions; Leerink Partners is exclusive placement agent and Ropes & Gray is company counsel.
Analysis · ZLAB · Life Sciences
Zai Lab is raising roughly $250 million by selling 11.34 million new ADSs at $22.04 apiece to a blue-chip biotech investor group led by TCGX — real cash that extends the runway for its lead DLL3 ADC, zoci, but paid for with new shares. The price sits just below today's $22.87 quote, so this is a market-level raise rather than a distressed discount, and the caliber of the buyer list (RA Capital, Wellington, Frazier, Cormorant, RTW) is itself a vote on the pipeline. The trade-off is dilution: 11.34 million ADSs against a company with a $2.58 billion market cap is a meaningful slug of new stock, and the resale registration plus a 60-day issuance standstill mean the overhang is now formalized. Closing is expected on or about October 27, 2026, subject to customary conditions.
How filings like this one have moved
In the 30 days to Oct 23, 2026, 36.8% of the 1044 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.77%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ZLAB was trading at $22.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $15.96 to $29.49. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.